Charles River Laboratories International, Inc. CRL SPXR3KPHARMA
Company Overview
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization. Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Why Investors Should Care
Operating margin of 15.1% supports profitability.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $4.02B (-0.9% YoY); net profit $-144.34M.
- Trailing 12 Months Year-on-year growth — revenue -2.7%, earnings -750.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 6.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 6.88% |
| 1 Year: | -2.70% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -750.08% |
Stock Price Performance
| 1 Year: | +86.13% |
| 6 Months: | +65.37% |
| 3 Months: | +59.09% |
| 1 Month: | +8.66% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)60.05 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CRL Charles River Laboratories International, Inc. SPXR3KPHARMA | 288.50 | -59.98 | $13.77B | 0.00% | 0.42% | -7.52% | 6.88% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Apr 2017 | Jul 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Apr 2023 | Jul 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 445.76M | 469.13M | 464.23M | 478.48M | 493.97M | 585.30M | 585.29M | 601.53M | 604.57M | 657.57M | 667.95M | 691.14M | 707.06M | 682.58M | 743.30M | 790.99M | 824.57M | 914.61M | 895.94M | 913.93M | 973.13M | 989.16M | 1.03B | 1.06B | 1.03B | 1.01B | 1.03B | 1.01B | 984.17M | 1.03B | 1.00B | 995.83M | 1.00B |
| Gross Profit | 132.78M | 138.07M | 140.57M | 140.77M | 169.75M | 156.27M | 179.88M | 171.35M | 185.32M | 176.85M | 167.39M | 181.47M | 215.98M | 216.20M | 226.42M | 211.78M | 238.10M | 246.12M | 262.31M | 252.06M | 232.24M | 289.27M | 299.97M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | 55.73M | 55.44M | 52.27M | 51.47M | 58.06M | 58.80M | 69.09M | 69.71M | 81.69M | 74.06M | 62.83M | 67.83M | 76.71M | 84.36M | 102.48M | 69.79M | 79.77M | 92.80M | 108.79M | 94.28M | 76.77M | 132.75M | 128.93M | 123.70M | 137.55M | 155.80M | 148.78M | 187.41M | 150.98M | 167.89M | 164.94M | 151.50M | 125.98M | 151.65M | 117.41M | 74.67M | 100.13M | 133.80M | 119.90M | 119.89M |
| Net Income | 48.51M | 37.38M | - | 37.14M | 35.21M | 37.73M | - | 46.78M | 53.95M | 52.47M | -29.85M | 52.63M | 53.71M | 60.37M | 59.66M | 55.13M | 43.73M | 72.81M | 80.35M | 50.77M | 67.44M | 102.91M | 143.19M | 61.53M | 88.45M | 103.43M | 93.02M | 109.32M | 96.47M | 103.13M | 97.02M | 87.39M | 72.96M | 94.08M | 69.66M | 25.47M | 52.33M | 54.42M | -14.84M | -1.48M |
| Diluted EPS | 1.02 | 0.79 | 0.67 | 0.78 | 0.73 | 0.79 | 0.93 | 0.97 | 1.12 | 1.08 | -0.63 | 1.08 | 1.10 | 1.22 | 1.21 | 1.11 | 0.88 | 1.46 | 1.61 | 1.02 | 1.34 | 2.03 | 2.81 | 1.20 | 1.72 | 2.01 | 1.81 | 2.13 | 1.88 | 2.01 | 1.89 | 1.69 | 1.30 | 1.74 | 1.33 | 0.50 | 1.06 | 1.10 | -0.30 | -0.03 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.30B | 1.17B | 1.13B | 1.14B | 1.13B | 1.17B | 1.30B | 1.36B | 1.68B | 1.86B | 2.27B | 2.62B | 2.92B | 3.54B | 3.98B | 4.13B | 4.05B | 4.02B |
| Operating Income | -451.84M | 169.61M | -298.51M | 174.31M | 165.76M | 151.40M | 177.67M | 206.45M | 237.55M | 288.28M | 331.38M | 351.15M | 432.73M | 589.86M | 650.98M | 617.26M | 227.35M | 25.16M |
| Net Income | -524.50M | 114.44M | -336.67M | 109.57M | 97.30M | 102.83M | 126.70M | 149.31M | 154.76M | 123.36M | 226.37M | 252.02M | 364.30M | 390.98M | 486.23M | 474.62M | 22.20M | -144.34M |
| Diluted EPS | -7.80 | 1.74 | -5.38 | 2.14 | 2.01 | 2.12 | 2.66 | 3.13 | 3.23 | 2.54 | 4.62 | 5.07 | 7.20 | 7.60 | 9.48 | 9.22 | 0.20 | -2.91 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 2.20B | 1.73B | 1.56B | 1.59B | 1.63B | 1.87B | 2.07B | 2.71B | 2.93B | 3.86B | 4.69B | 5.49B | - | 7.60B | 8.20B | 7.53B | 7.14B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.44B | 1.61B | 1.40B | 1.45B |
| Cash & Equivalents | 225.45M | 243.59M | 182.57M | 179.16M | 68.91M | 109.69M | 155.93M | 160.02M | 117.95M | 117.63M | 163.79M | 195.44M | 238.01M | 228.42M | - | 233.91M | 276.77M | 194.61M | 213.77M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 255.81M | 380.26M | 278.54M | 299.10M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 559.41M | 578.08M | 527.71M | 518.73M |
| Total Liabilities | - | - | 830.27M | 1.04B | 1.03B | 983.14M | 968.10M | 1.17B | 1.30B | 1.86B | 1.87B | 2.52B | 3.03B | 3.35B | - | 4.58B | 4.54B | 4.02B | 3.92B |
| Current Liabilities | - | - | 249.77M | 259.78M | 216.80M | 342.25M | 247.03M | 294.69M | 311.76M | 429.59M | 463.50M | 558.22M | 710.18M | 839.75M | - | 1.09B | 1.06B | 994.10M | 1.12B |
| Long Term Debt | - | - | - | 670.22M | 703.17M | 527.08M | 641.81M | 722.04M | 821.04M | 1.19B | 1.09B | 1.63B | - | - | - | 2.71B | 2.65B | 2.21B | 2.11B |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.10B | 3.07B | 2.72B | 2.57B |
| Total Equity | 1.91B | 1.24B | 1.38B | 687.42M | 525.58M | 600.80M | 640.98M | 672.20M | 733.07M | 836.77M | 1.05B | 1.32B | 1.63B | 2.11B | - | 2.98B | 3.60B | 3.46B | 3.16B |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 50.94M | 51.34M | 51.14M | 49.22M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - | - | - | 316.90M | 318.07M | 441.14M | 480.94M | 546.58M | - | 619.64M | 683.90M | 734.58M | 737.65M |
| Investing Cash Flow | - | - | - | - | - | - | - | - | -692.67M | -72.59M | -955.00M | -681.50M | -601.54M | - | -607.92M | -563.15M | -245.09M | -209.32M |
| Financing Cash Flow | - | - | - | - | - | - | - | - | 380.76M | -208.48M | 558.06M | 231.94M | 47.25M | - | -42.40M | -85.52M | -550.93M | -536.73M |
| Capital Expenditure | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -324.73M | -318.53M | -232.97M | -219.15M |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 294.91M | 365.37M | 501.61M | 518.49M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -30.68M | 35.22M | -61.44M | -8.40M |
| Share Buybacks | 115.06M | 45.90M | 356.53M | 283.80M | 64.19M | 165.93M | 122.02M | 117.48M | 12.27M | 106.91M | 13.85M | 18.09M | 23.98M | 40.71M | 38.65M | 24.16M | 119.17M | 360.67M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -34.9% | 14.5% | -26.3% | 15.3% | 14.7% | 13.0% | 13.7% | 15.1% | 14.1% | 15.5% | 14.6% | 13.4% | 14.8% | 16.7% | 16.4% | 14.9% | 5.6% | 0.6% |
| Net Margin % | -40.5% | 9.8% | -29.7% | 9.6% | 8.6% | 8.8% | 9.8% | 11.0% | 9.2% | 6.6% | 10.0% | 9.6% | 12.5% | 11.0% | 12.2% | 11.5% | 0.5% | -3.6% |
| ROE % | -42.2% | 8.3% | -49.0% | 20.8% | 16.2% | 16.0% | 18.8% | 20.4% | 18.5% | 11.8% | 17.2% | 15.4% | 17.2% | - | 16.3% | 13.2% | 0.6% | -4.6% |
| ROCE % | - | 8.7% | -20.3% | 13.0% | 13.3% | 10.9% | 11.3% | 11.8% | 10.4% | 11.7% | 10.0% | 8.8% | 9.3% | - | 10.0% | 8.6% | 3.5% | 0.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 8.88% | 4.24M | $1.24B |
| 2 | Blackrock Inc. | 7.96% | 3.80M | $1.11B |
| 3 | Vanguard Capital Management LLC | 6.60% | 3.15M | $918.02M |
| 4 | Invesco Ltd. | 6.25% | 2.98M | $870.06M |
| 5 | Harris Associates L.P. | 4.69% | 2.24M | $653.29M |
| 6 | Vanguard Portfolio Management LLC | 4.63% | 2.21M | $644.50M |
| 7 | Allspring Global Investments Holdings, LLC | 3.99% | 1.91M | $555.38M |
| 8 | State Street Corporation | 3.91% | 1.86M | $543.44M |
| 9 | Dimensional Fund Advisors LP | 3.45% | 1.65M | $480.52M |
| 10 | Ariel Investments, LLC | 3.16% | 1.51M | $439.05M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CRL
Is This the Right Time to Add CRL Stock to Your Portfolio? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxNbVRoRzZOb2lOZGRVOHJLamp1MzBidmNPSlQ0eHJtU1NtQnZrVktHWW9RSWNWMGY4cngwWWhseUVxbS1qSVNFNm1GbEc1LU82SFhlbjlVY1U5RU43VmlEZHhhY1FQRk5uQWVUaERjeFFiSEVUUmVlalpTTWNfcVN2TlpldFloa3A3OHVLWG…
Why Charles River Laboratories (CRL) Stock Is Up Today - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxNSV96a0YxVkxnR0UzNm12SU82SE1ENVVWN0h6MzRISWo5ZVdNQUZvbDgxNDV1RUdSV1ZremdzWEdLbnY1Ylc0emdDTURCOXIyMTVIMGctbHkxS1ZOX0VFOE9RUnNqZ2kwZmlycFozbE1EQ01qdFN0eWRURUhxc0VCZF9OVnBqdDZvNDl3dH…
How Investors Are Reacting To Charles River (CRL) Deepening Its Role In Complex Vaccine Development - simplywall.st
<a href="https://news.google.com/rss/articles/CBMigAJBVV95cUxPUUhFWjVlNEVFXzNmdF9sdGZhNEtzNndmX0cwMWtqY05KcXRrYlVqVE1LaEh2dk5qOFlQeVZHcWp0QUNFa0lHZXM3V1lxLTR3b2JGb3ZuZldLTTRYQVQtbTlVVHRYVE84eFotazlnaEhuT2hxWlBxNFpKVEs2REY4Q2l6anVNQkRBMGVKZV…
Charles River Laboratories International Inc (CRL) Shares Surge 3.3% -- What GF Score of 70 Tells Investors - GuruFocus
<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxQbDJUZENIQU5GSDlXcTZyMDJXZ2Zpa0NKMGJlSUJ1WkpQdVpiMFkyTTlIYjNQOEZyYktxWU5mTDk5dlFzWWlOYUVnZmdEYXBJY3BfTnk5MTJ4SC0tWDVsN2VKSnVGVjVIc05iRGdud1IxNzR1Q0lfQVRYel9RSl91Zk5GS1EzYzhCQTFNRW…
Charles River Laboratories (CRL) Stock Analysis: Navigating Growth Challenges with Strategic Collaborations - DirectorsTalk Interviews
<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxNdkg2Yk9JYVJSenFHSDc5cEREdXo1bGdhU0xOMmg0elY2WEhqcHFSSUp4VUNYYWFIOTYyZENRTnNHVlR4MS1MSjgxRFc0bGxaVTFoS1A3YmNmY3pPc3lfQTJNdkRCVTJoVlpoVEdxODlwNkhMT0oyMnpXODZLZzd5MjdMUm5rT3l2YkY1bF…
Charles River Laboratories International Stock 7-Day Winning Spree: Stock Climbs 26% - Trefis
<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxOd0dVM0RJODFOWmg2YWVOeUVnNmY5REhvUWxxS1pNMTA1NkVMZFFZa3diQ1JxN19OclAxVGlFRTByX2VrdkxLVEh5RHdXMXo5MHpPNWlMR0FGSE01bzRtVjZBam5DbDlfdE5FSDltdE1Cb1UzV0kzZ0xqeUFGZzlvWW5idnRCSGFBNnh1OV…
CRL — Frequently Asked Questions
What is the current share price of Charles River Laboratories International, Inc. (CRL)?
As of 2026-09-07 16:24 PDT, Charles River Laboratories International, Inc. (CRL) trades at $288.50 on NYSE. Its 52-week range is $145.57 to $298.58.
What is the market capitalisation of CRL?
Charles River Laboratories International, Inc. (CRL) has a market capitalisation of $13.77B on NYSE.
What is the P/E ratio of CRL?
CRL trades at a trailing price-to-earnings (P/E) ratio of -59.98. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 4.50.
What is the return on equity (ROE) of CRL?
CRL has a return on equity (ROE) of -7.52%. Its return on capital employed (ROCE) is 0.42%.
Is CRL a good stock to buy?
This page provides a data-driven analysis of Charles River Laboratories International, Inc. (CRL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.